Royalty Report: Drugs, Hormones, Disease – Collection: 385608

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Drugs
  • Hormones
  • Disease
  • Therapeutic
  • Pharmaceuticals
  • Pain
  • Estrogen Replacement Therapy
  • Delivery
  • Osteoarthritis
  • Tissue

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 385608

License Grant
Licensor grants to Licensee of the Cayman Islands an exclusive, right and license under the Fablyn Technology to make, have made, use, sell, have sold, import and export Products in the Field in the Territory.
License Property
Licensor owns or has rights under certain patent rights and know-how which relate to Fablyn.

Fablyn means lasofoxifene tartrate.  Fablyn (lasofoxifene tartrate) is a selective estrogen receptor modulator (SERM) intended for the treatment of osteoporosis in postmenopausal women.

Field of Use
Fablyn (lasofoxifene) is a selective estrogen receptor modulator (SERM) that was approved in the EU in 2009 for the treatment of osteoporosis in post-menopausal women at increased risk of fracture.

IPSCIO Record ID: 3014

License Grant
The Company has the licensing right for drugs that were designed for the treatment of post-menopausal women.
License Property
Lasofoxifene is a selective estrogen receptor modulator being developed to prevent osteoporosis in postmenopausal women in Phase III trials. The drug has been found to reduce bone loss and lower cholesterol levels without the breast or uterine cancer risks common in hormonal therapies.
Field of Use
Lasofoxifene (Fablyn®) is a product candidate that resulted from our collaboration with the Licensee. The Licensee submitted an NDA and an MAA for Fablyn for osteoporosis treatment in December 2007 and January 2008, respectively. The FDA Advisory Committee in September 2008 voted 9-3 in favor of approving this drug. In January 2009, the Licensee received a complete response letter from the FDA requesting additional information for Fablyn. In February 2009, Fablyn received approval in the EU for the treatment of osteoporosis.

IPSCIO Record ID: 385607

License Grant
This amendment modifies royalties and clarifies Anti-corruption compliance.
License Property
The original agreement is for Fablyn (lasofoxifene tartrate), a selective estrogen receptor modulator (SERM) intended for the treatment of osteoporosis in postmenopausal women.

Pradefovir is a prodrug that targets adefovir to the liver for the treatment of hepatitis B.

Field of Use
HepDirect technology license is for the discovery, development and commercialization of new compounds in hepatitis B (HepB), hepatitis C (HepC) and hepatocellular carcinoma (HCC).

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Hepatocellular carcinoma occurs most often in people with chronic liver diseases, such as cirrhosis caused by hepatitis B or hepatitis C infection.

IPSCIO Record ID: 1011

License Grant
The Company granted to Licensee an exclusive, nontransferable, worldwide license to develop, make, have made, use, sell, have sold, import and export a novel formulation of lasofoxifene intended for an under served market in women’s health.
Field of Use
Lasofoxifene is an estrogen partial agonist for osteoporosis treatment and other diseases. The oral, 0.5 mg form of lasofoxifene tartrate was developed under the trade name Fablyn.

IPSCIO Record ID: 314345

License Grant
Finnish Licensor grants Finnish Licensee an exclusive license subject to the terms and conditions hereof, to Licensors rights in the Invention and Patents. Licensor shall not for the term of this Agreement exercise the rights itself nor grant any of said rights to any third party.

Licensee shall have the right to sublicense the rights granted to it under this Agreement to any third party or parties.

License Property
Invention shall mean the invention described in the appendix to the invention notification 'Uudet trifenyylibutaani ja-buteenijohdannaiset' dated July 29 1997 provided by the inventors to Licensor, including without limitation the therein identified compounds.  The Invention and Patents relate to triphenylalkene derivatives and their use as selective estrogen receptor modulators (Serms). Estrogens have been known as female sex hormones. However, lately many tissue-specific properties for estrogens have been described in organs, which are not classically considered to be estrogen-sensitive or estrogen- 20 responsive. During the menopause the secretion of estrogens
is dramatically decreased. Subsequently elderly women develop commonly climacteric symptoms including hot flushes, sweating, insomnia, depression, headache, vaginal dryness, cardiovascular symptoms, urinary incontinence, swelling feeling, breast tenderness and fatigue. In long-term estrogen deficiency induces cardiovascular disorders and osteoporosis which increase the risk of bone fractures and  hospitalizations.

Patents shall mean granted US patent No 6,576,645 and its divisional allowed US patent application No 10/408,303, both titled 'Triphenylalkene derivatives and their use as selective estrogen receptor modulators' and any corresponding issued patent or filed patent application based on the inventions described in US patent 6,576,645 or the US patent application 10/408,303 that are filed or granted in any country of the world including any corresponding patent applications filed in any country or territory, or based on any divisionals, continuations, continuations-in-part, reissues, re-examinations, and extensions of any of the foregoing (including any 'patent term restoration' period or supplementary protection certificate granted under applicable laws in a given country).
Patent #6,576,645 – Triphenylalkene derivatives and their use as selective estrogen receptor modulators

Product(s) shall mean any pharmaceutical product containing i) any of the compounds identified in the Invention as its active ingredient alone or in combination of other active ingredients; ii) any molecule that has similar pharmacological properties with such compounds and falls within the claims of the Patents.

Field of Use
The Field of Use is for the use of novel selective estrogen receptor modulators (SERMs) and their pharmaceutical preparations in men and women for the treatment of degenerative diseases and symptoms due to estrogen deficiency. Estrogens have been known as female sex hormones.

Licensee a pharmaceutical company focused on discovering, licensing, developing and commercializing compounds in the endocrine, metabolic and cardiovascular therapeutic areas relating to the treatment of hormone deficiencies that result from aging in men and women.

IPSCIO Record ID: 356972

License Grant
Licensor grants a worldwide, exclusive, even as to Licensor, license, with the right to grant sublicenses, under the Licensed Technology, to make, have made, use, sell, offer for sale and import and otherwise Commercialize Licensed Products in the Field in the Territory.
License Property
Licensor is a corporation with proprietary transdermal drug delivery technology, and, has completed a Phase 2 Clinical Trial for a patch utilizing a micro-projection system containing a once-daily formulation of parathyroid hormone (PTH) and a Phase 1 Clinical Trial for such a patch containing a once-weekly formulation of PTH.

Licensed Products means the Daily Product and any Product Patch with a New Dosing Duration.

Daily Product means a Product Patch which is intended to deliver PTH formulations to a patient one time each day.

New Dosing Duration shall be any dosing duration, other than once daily, with respect to a Product Patch or Licensed Product. For example, if a Licensed Product has an administration once daily, then a once weekly administration would be a New Dosing Duration.

Pen means the pre-filled cartridge pen device currently marketed by Licensee to administer via injection once daily formulations of the Licensee’s recombinant human PTH analog (1-34) rhPTH (1-34) or manufactured by Licensee to administer a placebo.

Product Patch means a micro-projection array which pierces through the outmost, the stratum corneum, layer of the skin and either in which the micro-projections are coated with a formulation containing PTH as an active pharmaceutical ingredient, to deliver such active pharmaceutical ingredient into or through the skin, in a passive, diffusion-mediated manner, or to form pathways for diffusion-mediated delivery of PTH as an active pharmaceutical ingredient into or through the skin, in each inclusive of an applicator device, API, patch and packaging. For purposes of clarity, the Product Patch shall include all dosage and timed release formulations of PTH.

Field of Use
Field means all uses of PTH.

Licensee currently markets Forteo®, a once-daily formulation of Licensee’s recombinant human PTH analog (1-34) rhPTH(1-34) administered by subcutaneous injection and approved in the United States for the treatment of severe osteoporosis.

FORTEO is a prescription medicine used to treat postmenopausal women who have osteoporosis who are at high risk for having broken bones (fractures) or who cannot use other osteoporosis treatments. FORTEO can lessen the chance of broken bones (fractures) in the spine and other bones in postmenopausal women with osteoporosis. FORTEO is used to increase the bone mass in men with primary or hypogonadal osteoporosis who are at high risk for having broken bones (fractures) or who cannot use other osteoporosis treatments. FORTEO is used to treat both men and women with osteoporosis due to use of glucocorticoid medicines, such as prednisone, for several months, who are at high risk for having broken bones (fractures) or who cannot use other osteoporosis treatments.

IPSCIO Record ID: 4723

License Grant
The Licensor announced a License Agreement with the Licensee for oral lasofoxifene for the United States and additional territories.
License Property
Lasofoxifene is an estrogen partial agonist for the treatment of osteoporosis and other diseases.
Field of Use
The Licensee is a specialty pharmaceutical company focused on late-stage women’s health products.

IPSCIO Record ID: 60407

License Grant
Licensee is marketing bazedoxifene under the brand names Viviant and Conbriza in various territories for the treatment of postmenopausal osteoporosis. Licensee is responsible for the registration and worldwide marketing of bazedoxifene.
License Property
Bazedoxifene is a synthetic drug specifically designed to reduce the risk of osteoporotic fractures while also protecting uterine tissue.
Field of Use
Licensee has combined bazedoxifene with the active ingredient in Premarin to create Duavee, a combination therapy for the treatment of post-menopausal symptoms in women. Duavee is approved in the United States and it is anticipated that it will be marketed under the brand name Duavive in the EU.

IPSCIO Record ID: 266834

License Grant
The University of Finland assigns to the Licensee of Finland
—  all of its rights, title and interest in and to the Invention to the intent that the grant of any Patents thereon shall be in the name and vest of Licensee; together with all rights and powers arising or accrued therefrom including, but not limited to, the right to sue for damages and other remedies in respect of any infringement of such rights or other acts within the scope of any claims accompanying the Patent rights.
—  the right to apply for, prosecute and obtain Patent or similar protection throughout the world in respect of the Invention including, but not limited to the right to claim priority from any filed patent application to the intent that the grant of any Patents or similar protection shall be in the name of Licensee.
—  However, the University shall be entitled, free of any charge and without any compensation, to perpetually use the Invention, whether patented or not, for their further academic, non-commercial research and for teaching purposes. Right to commercially use and exploit any new invention which is related to the treatment or prevention of lower urinary tract symptoms or pelvic pain and which is directly and solely arising out of exercising such right shall be first offered to Licensee.
License Property
The University has the rights to an invention relating to the method for the treatment of prevention of lower urinary tract symptoms or pelvic pain with selective estrogen receptor modulators (SERMs).

The patent is titled Method for the Treatment or Prevention of Lower Urinary Tract Symptoms or Pelvic Pain.

Field of Use
The invention is for the use of aromatase inhibitors in the treatment of lower urinary tract symptoms (LUTS).
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.